Edwards Lifesciences (NYSE:EW) PT Raised to $92.00 at Evercore ISI

Edwards Lifesciences (NYSE:EW) had its price objective boosted by Evercore ISI from $86.00 to $92.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The brokerage presently has an “in-line” rating on the medical research company’s stock. Evercore ISI’s price objective points to a potential downside of 0.77% from the company’s current price.

Other equities analysts also recently issued research reports about the stock. Citigroup lifted their target price on shares of Edwards Lifesciences from $90.00 to $98.00 and gave the stock a “neutral” rating in a research note on Wednesday. StockNews.com lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Wednesday, March 20th. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating in a report on Thursday, March 7th. Morgan Stanley increased their price objective on shares of Edwards Lifesciences from $95.00 to $103.00 and gave the stock an “overweight” rating in a research report on Thursday, March 21st. Finally, OTR Global raised Edwards Lifesciences from a “mixed” rating to a “positive” rating in a research note on Tuesday, March 26th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and ten have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $90.67.

Edwards Lifesciences Trading Up 1.7 %

Shares of Edwards Lifesciences stock opened at $92.71 on Thursday. The firm’s 50 day moving average is $88.28 and its 200 day moving average is $76.82. The firm has a market capitalization of $55.80 billion, a PE ratio of 40.31, a price-to-earnings-growth ratio of 4.61 and a beta of 1.05. Edwards Lifesciences has a 1 year low of $60.57 and a 1 year high of $96.12. The company has a current ratio of 3.38, a quick ratio of 2.40 and a debt-to-equity ratio of 0.09.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Tuesday, February 6th. The medical research company reported $0.64 earnings per share for the quarter, meeting the consensus estimate of $0.64. Edwards Lifesciences had a return on equity of 23.56% and a net margin of 23.35%. The company had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.50 billion. During the same quarter last year, the business posted $0.64 EPS. Edwards Lifesciences’s revenue for the quarter was up 13.3% on a year-over-year basis. Equities research analysts forecast that Edwards Lifesciences will post 2.76 earnings per share for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Catherine M. Szyman sold 27,000 shares of the business’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $85.62, for a total value of $2,311,740.00. Following the sale, the vice president now directly owns 34,814 shares in the company, valued at $2,980,774.68. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other news, VP Catherine M. Szyman sold 27,000 shares of the business’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $85.62, for a total value of $2,311,740.00. Following the sale, the vice president now owns 34,814 shares of the company’s stock, valued at $2,980,774.68. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP Daniel J. Lippis sold 1,715 shares of the company’s stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $90.98, for a total transaction of $156,030.70. Following the sale, the vice president now owns 17,213 shares in the company, valued at $1,566,038.74. The disclosure for this sale can be found here. Insiders sold a total of 189,604 shares of company stock worth $16,593,546 in the last quarter. Insiders own 1.29% of the company’s stock.

Hedge Funds Weigh In On Edwards Lifesciences

Several hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. grew its position in Edwards Lifesciences by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 52,363,400 shares of the medical research company’s stock worth $3,992,709,000 after buying an additional 729,984 shares in the last quarter. State Street Corp grew its holdings in shares of Edwards Lifesciences by 0.4% during the second quarter. State Street Corp now owns 27,053,304 shares of the medical research company’s stock worth $2,551,938,000 after purchasing an additional 108,102 shares in the last quarter. Alliancebernstein L.P. grew its holdings in shares of Edwards Lifesciences by 0.3% during the second quarter. Alliancebernstein L.P. now owns 20,512,235 shares of the medical research company’s stock worth $1,934,919,000 after purchasing an additional 66,763 shares in the last quarter. Brown Advisory Inc. increased its position in shares of Edwards Lifesciences by 20.1% in the fourth quarter. Brown Advisory Inc. now owns 18,181,420 shares of the medical research company’s stock worth $1,386,333,000 after purchasing an additional 3,048,274 shares during the last quarter. Finally, Wellington Management Group LLP raised its stake in Edwards Lifesciences by 2.4% in the fourth quarter. Wellington Management Group LLP now owns 16,827,510 shares of the medical research company’s stock valued at $1,283,098,000 after purchasing an additional 393,109 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.